Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

July 1, 2017

Study Completion Date

September 30, 2017

Conditions
Diabetic Peripheral Neuropathy
Interventions
DEVICE

Erchonia® FX-635™

The Erchonia® FX-635™ is made up of 3 independent 17 mW, 635 nm red laser diodes that are applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.

DEVICE

Placebo Laser

The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light. It is applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.

Trial Locations (2)

85204

Arizona Institute of Footcare Physicians, Mesa

Unknown

Midleton Foot Clinic, Midleton

Sponsors
All Listed Sponsors
lead

Erchonia Corporation

INDUSTRY